← All devices 
Non-invasive glucose (pre-clinical) · Other · by Know Labs
KnowU (Know Labs)
A needle-free glucose monitor using radiofrequency spectroscopy — chasing the long-failed "holy grail" of non-invasive CGM.
Pre-clinicalKnowU
Newly launched0 mo old
API access: No Raw data access: No Open source: No public repo
Clinical value
28/100
Pre-clinical, unproven
Empowerment
35/100
Onboard ML, data TBD
Everyday value
45/100
Needle-free concept
A cuffless, needle-free glucose device that uses radiofrequency dielectric spectroscopy with onboard machine learning, aiming to become the first truly non-invasive CGM — a class with a long history of failure due to skin, melanin and hydration noise.
What it measures
Aims to estimate blood glucose non-invasively via RF dielectric spectroscopy; accuracy is still being established in trials.
Regulatory status
Pre-clinical / in FDA trials; not cleared. The FDA warned in 2024 against unauthorized non-invasive glucose wearables.
Validation & accuracy
Non-invasive glucose must overcome severe signal-to-noise challenges; independent validation is pending and the category is heavily scrutinized.
Data control & export
Data model not finalized; onboard ML suggests local processing, but consumer export/API terms are undefined.
Wearability & battery
Targets a cuffless, needle-free form factor; current devices are developmental.
Cost & access
Not yet on market.
Who it serves
People with or at risk of diabetes who want glucose insight without fingersticks or sensors — if it can be proven.
Who is left out or burdened
Unproven and uncleared; FDA has cautioned against this device class; risk of erroneous readings.
✓ Strengths
- Needle-free, cuffless glucose concept
- Onboard machine learning
- Targets the non-invasive "holy grail"
- Active FDA trial pathway
✕ Weaknesses
- Pre-clinical and uncleared
- Device class historically fails
- FDA cautioned against the category
- Accuracy unproven
28
Why this clinical score. Non-invasive glucose would be transformative, but pre-clinical status, an unproven device class, and explicit FDA caution keep the clinical score very low for now.
35
Why this empowerment score. Onboard ML hints at local data control, yet with no defined consumer data model the empowerment score is provisional.
45
Why this everyday score. A truly needle-free monitor would be highly livable; today it is developmental.
Latest news
Reviews & coverage
Coverage frames KnowU as an ambitious bid for the long-elusive non-invasive CGM using RF spectroscopy, while underscoring that the device class has repeatedly failed and KnowU remains pre-clinical and uncleared. Reviewers cite the FDA’s 2024 warning about unauthorized non-invasive glucose wearables.
Summary is a draft synthesis of public coverage, not an endorsement. Links open a search of each outlet.
Reddit communities
Independent user communities where this device (or its category) is discussed.
Get it · manuals & support
Draft profile · public-source review, June 2026 · scores describe direction and degree, not buying advice. News, links, and prices change — verify with the manufacturer. Image is representative.